Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 January 2015Website:
http://www.traconpharma.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 28 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
TCON Latest News
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2024 Earnings Conference Call is scheduled for May 14, 2024 at 4:30 PM ET. Presenting on the call will be Charles Theuer, President & CEO, and Scott Brown, CFO. Joining the call will be Matthew Venezia from Alliance Global Partners. Thank you for joining us today. Please note that all participants are currently in listen-only mode.
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2023 financial and operating results after the close of U.S. financial markets on Tuesday, March 5, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Tuesday as investors react to a licensing agreement for its product development platform ( PDP ). According to a press release from the company, it has licensed this to a clinical-stage biotech company for an upfront payment of $3 million.
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is falling on Monday as the company's shares retreat from a massive rally on Friday. That rally saw shares of TCON stock climb 43.9% higher during normal trading hours.
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Friday after the biopharmaceutical company announced results for the third quarter of 2023. Tracon Pharmaceuticals starts its report with adjusted earnings per share of 29 cents.
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants Dr. Charles Theuer - President and CEO Scott Brown - CFO Conference Call Participants Ed White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Third Quarter 2023 Earnings Conference Call.
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overview:
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q2 2023 Earnings Call August 14, 2023 4:30 PM ET Company Participants Charles P. Theuer - President and CEO Scott B.
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Monday, August 14, 2023. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Edward White - H.C. Wainwright & Co., LLC Joel Beatty - Robert W.
What type of business is TRACON Pharmaceuticals?
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
What sector is TRACON Pharmaceuticals in?
TRACON Pharmaceuticals is in the Healthcare sector
What industry is TRACON Pharmaceuticals in?
TRACON Pharmaceuticals is in the Biotechnology industry
What country is TRACON Pharmaceuticals from?
TRACON Pharmaceuticals is headquartered in United States
When did TRACON Pharmaceuticals go public?
TRACON Pharmaceuticals initial public offering (IPO) was on 30 January 2015
What is TRACON Pharmaceuticals website?
https://www.traconpharma.com
Is TRACON Pharmaceuticals in the S&P 500?
No, TRACON Pharmaceuticals is not included in the S&P 500 index
Is TRACON Pharmaceuticals in the NASDAQ 100?
No, TRACON Pharmaceuticals is not included in the NASDAQ 100 index
Is TRACON Pharmaceuticals in the Dow Jones?
No, TRACON Pharmaceuticals is not included in the Dow Jones index
When does TRACON Pharmaceuticals report earnings?
The next expected earnings date for TRACON Pharmaceuticals is 14 August 2024